ESMO 2019: Tailored Boost of Nivolumab Plus Ipilimumab May Benefit Some Patients With Renal Cell Carcinoma
Further follow-up is needed to determine duration and depth of response
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.